Printer Friendly

AMERICAN HOME PRODUCTS AND ELI LILLY AND COMPANY ANNOUNCE MARKETING AGREEMENT

 AMERICAN HOME PRODUCTS AND ELI LILLY AND COMPANY
 ANNOUNCE MARKETING AGREEMENT
 NEW YORK, March 5 /PRNewswire/ -- Whitehall Laboratories, division of American Home Products Corporation (NYSE: AHP), and Eli Lilly and Company today announced an agreement to develop and market over-the- counter formulations of Axid (nizatidine), the prescription anti-ulcer product.
 The agreement gives Whitehall exclusive rights to market nizatidine products over-the-counter in the United States and certain markets worldwide. This is the first time Lilly has entered into an agreement with another pharmaceutical manufacturer to develop and market an OTC version of a prescription product currently marketed by Lilly.
 Sidney Taurel, executive vice president, Lilly Pharmaceutical Division, stated, "This collaboration between Lilly and Whitehall marks a very important step for Lilly and the way the company will do business in the future. Strategic alliances, co-marketing agreements, and licensing agreements have become vital to the continued success of the pharmaceutical industry and an important part of Lilly's strategic direction."
 Bernard Canavan, M.D., president, American Home Products, stated, "This agreement demonstrates American Home Products' commitment to developing and marketing new and innovative products for the consumer marketplace. We are particularly pleased to have formed an alliance with Lilly, a company known for its diversified health care orientation, commitment to research and development, and professional sales and marketing efforts." The agreement with Eli Lilly and Company was signed in August 1989.
 Whitehall has proven experience in developing and gaining approval for marketing over-the-counter formulations of prescription products. The company launched Advil to the over-the-counter market in 1984. Among drugs previously available by prescription only, Advil remains one of the most successful OTC formulatie class of medicines known as H2 antagonists. Axid is used to treat duodenal ulcers and provides symptomatic relief and healing of reflux esophagitis. H2 antagonists are effective therapeutic agents in gastro-intestinal disorders caused or aggravated by excess stomach acid. They act by decreasing the amount of stomach acid produced.
 Since its introduction into the U.S. market in 1988, Axid has gained widespread acceptance by the medical community as a prescription product and is available in 26 countries worldwide.
 Eli Lilly and Company is a global-based corporation which develops, manufactures, and markets pharmaceuticals, medical instruments and diagnostic products and animal health products. The company markets its products in 110 countries around the world.
 American Home Products is a worldwide manufacturer and marketer of prescription drugs, medical supplies and diagnostic equipment, over-the- counter medicines and food products. Its Whitehall and Robins consumer divisions are marketers of leading over-the-counter medicines including Advil, Anacin, Robitussin, Dimetapp, Dristan, Primatene, and Preparation H.
 -0- 3/5/92
 /CONTACT: Karen Richards of American Home Products, 212-878-6923, or Ed West of Eli Lilly and Company, 317-276-3655/
 (AHP) CO: American Home Products Corp.; Eli Lilly and Company ST: New York, Indiana IN: MTC SU:


CK -- NY044 -- 5462 03/05/92 12:54 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 5, 1992
Words:475
Previous Article:SNO COUNTRY REPORTS OFFICIAL SKI REPORT FOR MARCH 5, 1992
Next Article:R.H. MACY & CO. TO CLOSE FIVE I. MAGNIN STORES
Topics:


Related Articles
LILLY AND NEXAGEN ENTER JOINT RESEARCH PROGRAM
TELIOS PHARMACEUTICALS SIGNS AN AGREEMENT WITH LILLY TO DEVELOP NOVEL OSTEOPOROSIS THERAPEUTICS
DIABETES STUDY LEADS TO HEALTHCARE COMPANY ALLIANCE; THREE COMPANIES CREATE EDUCATIONAL PARTNERSHIP
LILLY AND RANBAXY FORM A GLOBAL ALLIANCE
LILLY AND AUTOIMMUNE TO COLLABORATE IN THE DEVELOPMENT OF ORAL TOLERANCE PHARMACEUTICALS FOR TYPE I DIABETES
ELI LILLY & CO. TERMINATES FUNDING OF RESEARCH AGREEMENT WITH TELIOS PHARMACEUTICALS
Consilium(R) Announces Eli Lilly and Company Goes Live With FlowStream(R) Software
Scios and Lilly Enter Into Agreement for Alzheimer's Disease Research
Vertex and Eli Lilly Form Strategic Alliance to Develop Drugs to Treat Hepatitis C Infection
Snyder Signs Marketing Agreement with Eli Lilly & Co.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters